Similar articles

• Herceptin (trastuzumab): adjuvant and neoadjuvant trials.

  Yaal-Hahoshen N, Safra T. Yaal-Hahoshen N, et al. Isr Med Assoc J. 2006 Jun;8(6):416-21. Isr Med Assoc J. 2006. PMID: 16833172 Review. No abstract available.
• HER2-positive breast cancer: current treatment strategies.

  Perez EA, Baweja M. Perez EA, et al. Cancer Invest. 2008 Jul;26(6):545-52. doi: 10.1080/07357900801971024. Cancer Invest. 2008. PMID: 18584344 Review. No abstract available.
• Weighing a dose-dense option for adjuvant chemotherapy and trastuzumab in early-stage breast cancer.

  Mayer EL, Burstein HJ. Mayer EL, et al. J Clin Oncol. 2008 Mar 10;26(8):1198-200. doi: 10.1200/JCO.2007.14.8734. J Clin Oncol. 2008. PMID: 18323544 No abstract available.
• HER2 and response to paclitaxel in node-positive breast cancer.

  Roukos DH. Roukos DH. N Engl J Med. 2008 Jan 10;358(2):197; author reply 198. N Engl J Med. 2008. PMID: 18193530 No abstract available.
• [Advances in herceptin neoadjuvant therapy and adjuvant therapy of breast cancer].

  Wang LP, Shen KW, Shen ZZ. Wang LP, et al. Zhonghua Zhong Liu Za Zhi. 2006 Apr;28(4):241-3. Zhonghua Zhong Liu Za Zhi. 2006. PMID: 16875618 Review. Chinese. No abstract available.